These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 2808542

  • 1. Transforming growth factors type beta 1 and beta 2 are equipotent growth inhibitors of human breast cancer cell lines.
    Zugmaier G, Ennis BW, Deschauer B, Katz D, Knabbe C, Wilding G, Daly P, Lippman ME, Dickson RB.
    J Cell Physiol; 1989 Nov; 141(2):353-61. PubMed ID: 2808542
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Inhibition of colon and breast carcinoma cell growth by interleukin-4.
    Toi M, Bicknell R, Harris AL.
    Cancer Res; 1992 Jan 15; 52(2):275-9. PubMed ID: 1728401
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Characterization of epidermal growth factor receptor and action on human breast cancer cells in culture.
    Fitzpatrick SL, LaChance MP, Schultz GS.
    Cancer Res; 1984 Aug 15; 44(8):3442-7. PubMed ID: 6331647
    [Abstract] [Full Text] [Related]

  • 6. Characterization of estrogen responsive transforming activity in human breast cancer cell lines.
    Dickson RB, Bates SE, McManaway ME, Lippman ME.
    Cancer Res; 1986 Apr 15; 46(4 Pt 1):1707-13. PubMed ID: 2418952
    [Abstract] [Full Text] [Related]

  • 7. Growth stimulation of human breast cancer cells with anti-transforming growth factor beta antibodies: evidence for negative autocrine regulation by transforming growth factor beta.
    Arteaga CL, Coffey RJ, Dugger TC, McCutchen CM, Moses HL, Lyons RM.
    Cell Growth Differ; 1990 Aug 15; 1(8):367-74. PubMed ID: 2177634
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effects of pharmacological concentrations of estrogens on proliferation and cell cycle kinetics of human breast cancer cell lines in vitro.
    Reddel RR, Sutherland RL.
    Cancer Res; 1987 Oct 15; 47(20):5323-9. PubMed ID: 3652038
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. 20-epi-vitamin D3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines.
    Elstner E, Linker-Israeli M, Said J, Umiel T, de Vos S, Shintaku IP, Heber D, Binderup L, Uskokovic M, Koeffler HP.
    Cancer Res; 1995 Jul 01; 55(13):2822-30. PubMed ID: 7796409
    [Abstract] [Full Text] [Related]

  • 15. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro.
    Yoneda T, Williams PJ, Hiraga T, Niewolna M, Nishimura R.
    J Bone Miner Res; 2001 Aug 01; 16(8):1486-95. PubMed ID: 11499871
    [Abstract] [Full Text] [Related]

  • 16. Regulation of insulin-like growth factor-binding-protein-1, 2, 3, 4, 5, and 6: synthesis, secretion, and gene expression in estrogen receptor-negative human breast carcinoma cells.
    Sheikh MS, Shao ZM, Hussain A, Clemmons DR, Chen JC, Roberts CT, LeRoith D, Fontana JA.
    J Cell Physiol; 1993 Jun 01; 155(3):556-67. PubMed ID: 7684042
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines.
    Thompson EW, Paik S, Brünner N, Sommers CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME.
    J Cell Physiol; 1992 Mar 01; 150(3):534-44. PubMed ID: 1537883
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
    Masiakos PT, MacLaughlin DT, Maheswaran S, Teixeira J, Fuller AF, Shah PC, Kehas DJ, Kenneally MK, Dombkowski DM, Ha TU, Preffer FI, Donahoe PK.
    Clin Cancer Res; 1999 Nov 01; 5(11):3488-99. PubMed ID: 10589763
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.